SLC5A2 and heart failure: The DPP‐4 inhibitors belong to a class of widely used GLDs, which have been shown to be associated with CV safety in several large clinical trials, although concerns about increased heart failure risk have been raised.16, 17, 18 Being a widely used modern oral treatment for T2D, as is SGLT‐2 inhibitor treatment, DPP‐4 inhibitors are a well‐suited comparator for examining the effectiveness of another GLD.